Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Sherry Korczynski sold 8,750 shares of the company's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the transaction, the insider owned 235,689 shares in the company, valued at $1,230,296.58. This represents a 3.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Aquestive Therapeutics Stock Performance
Shares of AQST stock traded down $0.21 during trading on Friday, hitting $4.78. 2,295,311 shares of the company were exchanged, compared to its average volume of 3,068,932. The business's 50-day simple moving average is $4.38 and its 200 day simple moving average is $4.25. Aquestive Therapeutics, Inc. has a twelve month low of $2.93 and a twelve month high of $7.55. The firm has a market capitalization of $599.31 million, a price-to-earnings ratio of -7.32 and a beta of 1.48.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to the consensus estimate of $11.42 million. On average, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.5 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Monday, August 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Cantor Fitzgerald restated an "overweight" rating and issued a $11.00 price objective on shares of Aquestive Therapeutics in a report on Thursday. Finally, Wall Street Zen lowered shares of Aquestive Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $9.17.
Read Our Latest Report on AQST
Institutional Trading of Aquestive Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bratton Capital Management L.P. acquired a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $40,813,585. BlackRock Inc. bought a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth $33,569,000. Vanguard Group Inc. boosted its holdings in shares of Aquestive Therapeutics by 30.8% during the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company's stock worth $31,651,000 after buying an additional 1,333,627 shares during the period. State Street Corp grew its stake in Aquestive Therapeutics by 53.7% in the 4th quarter. State Street Corp now owns 2,462,778 shares of the company's stock valued at $15,910,000 after buying an additional 860,562 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Aquestive Therapeutics by 99.2% in the 1st quarter. Bank of America Corp DE now owns 2,405,050 shares of the company's stock valued at $9,981,000 after buying an additional 1,197,459 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company's stock.
About Aquestive Therapeutics
(
Get Free Report)
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
